Headache and Migraine

The FDA-approved preventive therapy for migraine was well-tolerated, with low dropout rates, and showed sustained clinically meaningful outcomes across a 2-year stretch.

Expert clinicians offer their perspectives on transitional care in pediatric MS, a biomarker for SUDEP, and a novel approach to narcolepsy, among other topics.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 26, 2021.

A discussion on how to measure the success of preventative migraine treatment.

Key opinion leaders explain the burden of disease that accompanies preventative migraine treatment.

The study is the first and only to compare the 2 anticalcitonin gene-related peptide medicines for migraine preventive treatment.

A migraine specialist examines the efficacy and safety of oral CGRP antagonist ubrogepant for the acute treatment of migraine.

Dr David Kudrow discusses how CGRP antagonist treatments have affected chronic migraine, including the effect on quality of life.

Although headache and COVID-19 have been linked together in the literature, more studies are needed to better understand the pathophysiology of these headaches and to determine the best treatment options.

Here's what is coming soon to NeurologyLive®.

Although not associated with diagnosis, investigators did conclude that substantial/very severe impact of headache attacks and anxiety were correlated with presence of insomnia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 19, 2021.

Expert neurologists share their goals and patient considerations for preventive migraine therapy.

Andrew C. Charles, MD, provides a historical perspective on the agents traditionally used for preventive migraine therapy.

An expert neurologist explains how to decide on migraine treatment with a patient and when to consider preventive treatment.

David Kudrow, MD, defines episodic and chronic migraine and details how symptoms differ.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending November 13, 2021.

Having previously served as head of the organization during the Obama administration, Califf will replace current Acting Commissioner Janet Woodcock, MD.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 12, 2021.

In the final 3 months of treatment in the first head-to-head study of these agents, 55.4% of those on erenumab achieved at least 50% reduction in monthly migraine days compared with 31.2% on topiramate.

Originally approved in 1996, the therapy, indicated for the treatment of to partial-onset and tonic clonic seizures, is now available in a liquid formulation.

Forget what you think you know about red wine or chocolate ‘activating’ migraine. Many commonly accepted “triggers” aren’t triggers at all.

Here's what is coming soon to NeurologyLive.